Our study identifies ACTN1 as a crucial contributor to cisplatin resistance and tumorigenesis in HNSCC, as evidenced across cellular, animal, and patient-derived xenograft models. This evidence concerns the gene ACTN1 and head and neck squamous cell carcinoma.